- Home
- FLYE vs RDHL Comparison
FLYE vs RDHL Comparison
Compare FLYE & RDHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FLYE
- RDHL
- Stock Information
- Founded
- FLYE 2018
- RDHL 2009
- Country
- FLYE United States
- RDHL Israel
- Employees
- FLYE N/A
- RDHL N/A
- Industry
- FLYE Aerospace
- RDHL Biotechnology: Pharmaceutical Preparations
- Sector
- FLYE Industrials
- RDHL Health Care
- Exchange
- FLYE Nasdaq
- RDHL Nasdaq
- Market Cap
- FLYE 10.2M
- RDHL 4.3M
- IPO Year
- FLYE 2024
- RDHL N/A
- Fundamental
- Price
- FLYE $4.67
- RDHL $1.91
- Analyst Decision
- FLYE
- RDHL
- Analyst Count
- FLYE 0
- RDHL 0
- Target Price
- FLYE N/A
- RDHL N/A
- AVG Volume (30 Days)
- FLYE 809.9K
- RDHL 15.6K
- Earning Date
- FLYE 08-18-2025
- RDHL 08-28-2025
- Dividend Yield
- FLYE N/A
- RDHL N/A
- EPS Growth
- FLYE N/A
- RDHL N/A
- EPS
- FLYE N/A
- RDHL N/A
- Revenue
- FLYE $28,547,111.00
- RDHL $8,042,999.00
- Revenue This Year
- FLYE N/A
- RDHL $381.91
- Revenue Next Year
- FLYE N/A
- RDHL N/A
- P/E Ratio
- FLYE N/A
- RDHL N/A
- Revenue Growth
- FLYE N/A
- RDHL 23.17
- 52 Week Low
- FLYE $1.65
- RDHL $1.71
- 52 Week High
- FLYE $36.50
- RDHL $20.28
- Technical
- Relative Strength Index (RSI)
- FLYE N/A
- RDHL 44.55
- Support Level
- FLYE N/A
- RDHL $2.00
- Resistance Level
- FLYE N/A
- RDHL $2.08
- Average True Range (ATR)
- FLYE 0.00
- RDHL 0.10
- MACD
- FLYE 0.00
- RDHL 0.01
- Stochastic Oscillator
- FLYE 0.00
- RDHL 37.05
About FLYE Fly-E Group Inc. Common Stock
Fly-E Group Inc is an electric vehicle company that is principally engaged in designing, installing and selling smart electric motorcycles, electric bikes, electric scooters and related accessories under the brand Fly E-Bike. It also provides connectivity solutions and value-added services to their customers.
About RDHL Redhill Biopharma Ltd.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is dedicated to advancing its development pipeline of clinical-stage therapeutic candidates. It also commercializes GI-related products in the U.S., including Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). Currently, the company's pipeline consists of five therapeutic candidates: Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, the majority of which are in clinical development.